



February 5, 2025

Company name Shin Nippon Biomedical Laboratories, Ltd.
Representative Ryoichi Nagata, Representative Chairman,
President & CEO
Listing TSE PRIME : ticker code 2395
Inquiries Toshiyuki Iwata, Executive Officer, Head of
Corporate Communications
TEL +81 3 5565 6216

Notice Regarding Revisions of Consolidated Earnings Forecasts **for the Full-Year of the Fiscal Year Ending March 31, 2025**

Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, “the Company”) announces the revisions to the forecast of the full-year consolidated results for the fiscal year ending March 31, 2025 (from April 1, 2024 to March 31, 2025) announced on May 8, 2024, in view of the latest earnings trends.

1. Revisions of the forecasts for the consolidated earnings results for the fiscal year ending March 31, 2025

Revisions of the forecasts for the full-year consolidated financial results from April 1, 2024 to March 31, 2025

	Revenue	Operating profit	Ordinary profit	Profit attributable to owners of parent	Profit per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous Forecasts (A)	29,835	2,350	5,345	3,920	94.15
Revised forecasts (B)	32,000	2,900	5,900	4,400	105.68
Changes (B - A)	+2,165	+550	+555	+480	
Changes (%)	+7.3	+23.4	+10.4	+12.2	
ref.) Results of the fiscal year ended March 31, 2024	26,450	4,162	7,015	5,531	132.86

2. Reasons for the revisions to the consolidate financial results forecasts

For the full-year ending March 31, 2025, we expect that the revenue will exceed the initial plan, considering the better-than-expected sales and orders received in nonclinical CRO business in the third quarter of the current fiscal year. The operating profit forecast is revised upwardly mainly due to lower-than-projected costs of the US subsidiary Satsuma Pharmaceuticals, Inc., some of which had been expected in the current fiscal year, are carried forward to the next fiscal year. The full-year ordinary profit is also revised upwardly, thanks to a higher-than-expected share of profit of entities accounted for using equity method from PPD-SNB K.K.

The newly revised forecast figures in the full-year outlook above continue to be based on the assumed exchange rate of 145.00 Japanese yen to the US dollar.

(NOTE) Financial forecasts and other statements above are based on information available as of the date of this announcement. Actual performance may differ substantially due to various factors in the future

END